- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02090361
Efficacy of Collagen-elastin Dermal Substitute in the Treatment of Loss of Cutaneous Substances With Skin Grafts (MATRIGREFFE)
In reconstructive surgery , most losses of cutaneous substance require the use of a thin skin graft . This technique allows epidermization of the defect by applying a thin layer of autologous epidermis. It does not reconstitute the injured skin. Transplants cause retractile scars, adherent to the deep plan, that may require revision surgery . Since a decade , dermal matrices are mainly used in burned skin centers . The collagen -elastin matrix has the advantage to set up in the same operation that the skin graft and contain elastic fibers , two assets which improve the results of skin grafting.
Objective:
Evaluation of the clinical efficacy of the addition of a dermal matrix to skin graft on Skin Foldability, at day 360.
Methodology:
This is a multicenter randomized study (CHU Caen , Amiens, Rouen and Lille)
Conduct of the study :
The transplant will be performed according to the protocol defined between inter -region surgeons. The implementation of the dermal matrix will be in the same surgical technique as thin skin graft ( group 1 ) or the thin skin graft will be performed alone ( group 2) time .
Evaluation Criteria Main : Skin Foldability ( Uf ) assessed grafted site will be compared to the opposite side ungrafted evaluated at Day 360 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH).
To achieve the main objective, it is planned to compare the ratio between Uf graft site and the opposite healthy site between two groups: skin + matrix graft , or skin graft only. Thus, the Wilcoxon test for independent samples will be used to settle bilateral formulation between the null hypothesis ( there is no difference between the two groups ) and the alternative hypothesis ( there is a difference between the two groups ) . In determining the overall risk of first species to 5% and the power of this test to detect the 90% expected under the alternative hypothesis difference should be the main criterion for evaluating at least 59 patients in each group so 118 patients total.
Prospect If the contribution of a dermal matrix in loss of skin substances improves skin pliability and reduces pain , functional and aesthetic sequelae grafts thin skin , the dermal matrix may be proposed as a complementary treatment in these indications.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Isabelle AUQUIT-AUCKBUR, Pr
- Phone Number: 6621 +3323288
- Email: isabelle.auquit-auckbur@chu-rouen.fr
Study Contact Backup
- Name: Julien BLOT, M.
- Phone Number: 8265 +3323288
- Email: julien.blot@chu-rouen.fr
Study Locations
-
-
-
Amien, France
- Recruiting
- CHU d'Amiens
-
Contact:
- Raphael SINNA, Pr
-
Caen, France
- Recruiting
- CHU de Caen
-
Contact:
- Nathalie HANNOUZ, MD
-
Lille, France
- Recruiting
- CHU de Lille
-
Contact:
- Pierre GUERRECHI, MD
-
Rouen, France, 76031
- Recruiting
- UH Rouen
-
Contact:
- Isabelle AUQUIT-AUCKBUR, Pr
- Phone Number: 6621 +3323288
- Email: isabelle.auquit-auckbur@chu-rouen.fr
-
Principal Investigator:
- Isabelle AUQUIT-AUCKBUR, Pr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged over 18
- Signed informed consent
- Patients with loss of cutaneous substance of at least 15 cm2
- Patient Without bone exposure, vascular, joint or tendon
- Eligibility for surgical treatment by skin graft
- Loss of substance trauma (avulsion, burns) or surgery (skin excision)
Exclusion Criteria:
- Patient with a chronic wound
- Wound superinfected
- Patient unable for local or general skin graft
- Patient with an old or a recent skin injury strictly contralateral to the graft site.
- Patient unable to consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: skin graft with dermal matrix
Epidermization of the defect by applying a thin layer of autologous epidermis with addition of a dermal matrix
|
Epidermization of the defect by applying a thin layer of autologous epidermis
|
Placebo Comparator: skin graft - classic procedure
Epidermization of the defect by applying a thin layer of autologous epidermis
|
Epidermization of the defect by applying a thin layer of autologous epidermis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skin Foldability ( Uf )
Time Frame: Day 360
|
Skin Foldability ( Uf ) will be assessed on grafted site compared to the opposite side ungrafted at day D360 .
Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH).
|
Day 360
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skin Foldability ( Uf )
Time Frame: Day 180
|
Skin Foldability ( Uf ) will be assessed on grafted site compared to the opposite side ungrafted at day D180 .
Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH)
|
Day 180
|
Skin Foldability ( Uf )
Time Frame: Day 90
|
Skin Foldability ( Uf ) will be assessed on grafted site compared to the opposite side ungrafted at day D90 .
Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH)
|
Day 90
|
Pain on the grafted site
Time Frame: D7
|
Assessment of pain on the grafted site EVA at Day 7
|
D7
|
pain on the grafted site
Time Frame: Day 15
|
Assessment of pain on the grafted site at Day 15
|
Day 15
|
pain on the grafted site
Time Frame: Day 30
|
Assessment of pain at the grafted site EVA to D30
|
Day 30
|
pain on the grafted site
Time Frame: Day 90
|
Assessment of pain at the grafted site EVA at D30
|
Day 90
|
pain on the grafted site
Time Frame: Day 180
|
Assessment of pain at the grafted site EVA at Day 180
|
Day 180
|
pain on the grafted site
Time Frame: Day 360
|
Assessment of pain at the grafted site EVA at Day 360
|
Day 360
|
tolerance of matriderm use
Time Frame: Day 360
|
Occurrence within 360 days of a local complication requiring reoperation
|
Day 360
|
Area healed
Time Frame: Day 7
|
Evaluation of the percentage of area healed at Day 7
|
Day 7
|
Area healed
Time Frame: Day 15
|
Evaluation of the percentage of area healed at Day 15
|
Day 15
|
Area healed
Time Frame: Day 30
|
Evaluation of the percentage of area healed at Day 30
|
Day 30
|
Assessment of functional effects
Time Frame: Day 30
|
Assessment of functional effects of the scar on the patient 's daily activities defined at Day 30
|
Day 30
|
Assessment of functional effects
Time Frame: Day 90
|
Assessment of functional effects of the scar on the patient 's daily activities defined at Day 90
|
Day 90
|
Assessment of functional effects
Time Frame: Day 180
|
Assessment of functional effects of the scar on the patient 's daily activities defined at Day 180
|
Day 180
|
Assessment of functional effects
Time Frame: Day 360
|
Assessment of functional effects of the scar on the patient 's daily activities defined at Day 360
|
Day 360
|
Aesthetic sequelae evaluation
Time Frame: Day 90
|
Evaluation aesthetic sequelae by a committee of independent experts to study the photographs taken at day 90
|
Day 90
|
Aesthetic sequelae evaluation
Time Frame: Day 180
|
Evaluation aesthetic sequelae by a committee of independent experts to study the photographs taken at day 180
|
Day 180
|
Aesthetic sequelae evaluation
Time Frame: Day 360
|
Evaluation aesthetic sequelae by a committee of independent experts to study the photographs taken at day 360
|
Day 360
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Isabelle AUQUIT-AUCKBUR, Pr, UH Rouen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2013/008/HP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Graft
-
University of ArizonaTerminatedSkin Graft Complications | PRP | Skin Graft (Allograft) Rejection | Skin Graft DetachmentUnited States
-
Mundipharma Korea LtdCompleted
-
Shanghai Jiao Tong University School of MedicineShanghai Zhongshan Hospital; Ruijin Hospital; The First Affiliated Hospital of... and other collaboratorsNot yet recruiting
-
Cairo UniversityCompleted
-
University Hospital, Basel, SwitzerlandGottfried und Julia Bangerter- Rhyner-Stiftung, BaselRecruitingGraft Versus Host Disease | Skin Microbiome | Graft Versus Host Disease in SkinSwitzerland
-
Federico II UniversityRecruitingWounds and Injuries | Skin Graft Scar | Skin Graft ComplicationsItaly
-
Aalborg University HospitalCompleted
-
University of Southern CaliforniaRecruitingSkin Graft ComplicationsUnited States
-
Dow University of Health SciencesCompletedSkin Graft DetachmentPakistan
-
Bitop AGWithdrawnAcute Graft Versus Host Disease in SkinGermany
Clinical Trials on skin graft
-
Taipei Medical University WanFang HospitalCompletedSkin Regrafting; Donor Site of Skin Grafting; Vancouver Scar ScaleTaiwan
-
Indonesia UniversityRecruitingBurn Degree Second | Burn Degree ThirdIndonesia
-
University Hospital, GhentResearch Foundation FlandersCompletedBurns | Necrotizing Fascitis | Full Thickness BurnBelgium
-
Markman Biologics CorporationUnknown
-
First Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Hu ZhichengCompleted
-
Gillette Children's Specialty HealthcareUniversity of MinnesotaCompleted
-
University Hospital, GhentDutch Burnwound Foundation, NetherlandCompletedFull Thickness Skin DefectsBelgium
-
Nebraska Methodist Health SystemAcera Surgical, Inc.TerminatedHead and Neck CancerUnited States
-
Coordinación de Investigación en Salud, MexicoUnknownBurns | Skin UlcerMexico